SG11202000691XA - Oncolytic viral vectors and uses thereof - Google Patents
Oncolytic viral vectors and uses thereofInfo
- Publication number
- SG11202000691XA SG11202000691XA SG11202000691XA SG11202000691XA SG11202000691XA SG 11202000691X A SG11202000691X A SG 11202000691XA SG 11202000691X A SG11202000691X A SG 11202000691XA SG 11202000691X A SG11202000691X A SG 11202000691XA SG 11202000691X A SG11202000691X A SG 11202000691XA
- Authority
- SG
- Singapore
- Prior art keywords
- viral vectors
- oncolytic viral
- oncolytic
- vectors
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16645—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537359P | 2017-07-26 | 2017-07-26 | |
| US201862686802P | 2018-06-19 | 2018-06-19 | |
| PCT/US2018/043938 WO2019023483A1 (en) | 2017-07-26 | 2018-07-26 | Oncolytic viral vectors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000691XA true SG11202000691XA (en) | 2020-02-27 |
Family
ID=65040409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000691XA SG11202000691XA (en) | 2017-07-26 | 2018-07-26 | Oncolytic viral vectors and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11612625B2 (en) |
| EP (1) | EP3658165A4 (en) |
| JP (2) | JP7249323B2 (en) |
| KR (1) | KR20200042904A (en) |
| CN (1) | CN111212656A (en) |
| AU (1) | AU2018306455A1 (en) |
| BR (1) | BR112020001559A2 (en) |
| CA (1) | CA3070299A1 (en) |
| IL (1) | IL271993A (en) |
| MX (1) | MX2020000993A (en) |
| RU (1) | RU2771110C2 (en) |
| SG (1) | SG11202000691XA (en) |
| WO (1) | WO2019023483A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017212713B2 (en) | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| SG11202000691XA (en) | 2017-07-26 | 2020-02-27 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
| CA3085662A1 (en) * | 2017-12-14 | 2019-06-20 | Unicyte Ev Ag | Pharmaceutical carriers containing mirnas for use in the treatment of renal cancer |
| CN113164484A (en) * | 2018-11-29 | 2021-07-23 | 复诺健生物科技加拿大有限公司 | HSV vectors with reduced neurotoxicity |
| MX2021010458A (en) * | 2019-03-05 | 2021-09-21 | Amgen Inc | Use of oncolytic viruses for the treatment of cancer. |
| CN110283794B (en) * | 2019-05-30 | 2021-04-23 | 伍泽堂 | Recombinant oncolytic virus, preparation method, application and medicament thereof |
| CN111235274A (en) * | 2020-01-18 | 2020-06-05 | 山西医科大学第一医院 | Screening method of laryngeal squamous carcinoma serum exosome marker and application of exosome source miR-941 |
| EP4136242A2 (en) * | 2020-04-15 | 2023-02-22 | Humane Genomics | Artificial oncolytic viruses and related methods |
| TW202146029A (en) * | 2020-04-23 | 2021-12-16 | 輔仁大學學校財團法人輔仁大學 | Chemotherapy drug-sensitizing method, agent composition and use thereof |
| CN111494636A (en) * | 2020-06-22 | 2020-08-07 | 中国人民解放军空军军医大学 | Application of MCT1 inhibitor and pharmaceutical composition containing same |
| JP2023540427A (en) * | 2020-07-07 | 2023-09-25 | オリエンジーン バイオテクノロジー リミテッド | Guide RNA and method for HSV-1 gene editing |
| US11505607B2 (en) * | 2020-11-13 | 2022-11-22 | Binhui Biopharmaceutical Co., Ltd. | Bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition |
| CN116744951A (en) * | 2020-12-25 | 2023-09-12 | 苏州系统医学研究所 | Composition containing oncolytic virus and application thereof in tumor treatment |
| WO2022151078A1 (en) * | 2021-01-13 | 2022-07-21 | 嘉兴允英医学检验有限公司 | Oncolytic virus and application thereof |
| CA3212103A1 (en) * | 2021-03-24 | 2022-09-29 | Virogin Biotech Canada Ltd | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors |
| EP4170022A1 (en) * | 2021-10-19 | 2023-04-26 | Consejo Superior De Investigaciones Científicas | Recombinant african swine fever virus and uses thereof |
| CN114010666A (en) * | 2021-10-22 | 2022-02-08 | 上海交通大学 | Application of oncolytic virus, PARP inhibitor and PD-1 antibody in preparation of antitumor drugs |
| WO2023164442A2 (en) * | 2022-02-22 | 2023-08-31 | Vyro Bio Inc. | Oncolytic viruses and methods of use |
| WO2024054293A1 (en) * | 2022-09-08 | 2024-03-14 | Research Institute At Nationwide Children's Hospital | Oncolytic virus combination to maximize oncolytic activity |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
| JPH0668B2 (en) | 1985-08-30 | 1994-01-05 | 財団法人化学及血清療法研究所 | Recombinant plasmid with herpes simplex virus gene |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5849571A (en) | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| DK0641192T3 (en) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Transmucosal drug delivery device |
| US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6261552B1 (en) | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
| GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| AU8605598A (en) | 1997-07-31 | 1999-02-22 | University Of Pittsburgh | Targeted hsv vectors |
| IL136621A0 (en) | 1997-12-17 | 2001-06-14 | Immunex Corp | Cell surface glycoproteins associated with human b cell lymphomas |
| GB9810423D0 (en) | 1998-05-15 | 1998-07-15 | Cancer Res Campaign Tech | Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy |
| EP1002864A1 (en) | 1998-11-10 | 2000-05-24 | Universita' degli studi di Bologna | HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
| US6897057B1 (en) | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
| GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| US7749745B2 (en) | 2001-03-27 | 2010-07-06 | Georgetown University | Viral vectors and their use in therapeutic methods |
| US20020187126A1 (en) | 2001-04-06 | 2002-12-12 | Mount Sinai School Of Medicine | Methods for viral oncoapoptosis in cancer therapy |
| CA2462790A1 (en) | 2001-10-04 | 2003-04-10 | Immunex Corporation | Ul16 binding protein 4 |
| KR100900249B1 (en) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239 Immunogenic Plasmids And AIDS DNA Vaccine Containing The Same |
| US8927251B2 (en) | 2002-10-07 | 2015-01-06 | The University Of Chicago | Targeting of herpes simplex virus to specific receptors |
| AU2005206410A1 (en) | 2004-01-22 | 2005-08-04 | Dnavec Research Inc. | Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter |
| GB0406389D0 (en) | 2004-03-22 | 2004-04-21 | Istituto Superiore Di Sanito | Recombinant herpes simplex virus and uses therefor |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| JP5054522B2 (en) | 2004-08-20 | 2012-10-24 | ヴィラリティクス リミテッド | Methods and compositions for treating blood cancer |
| EP1805213B1 (en) | 2004-10-28 | 2015-11-18 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| EP1843773A4 (en) | 2005-01-17 | 2008-07-30 | Viralytics Ltd | Method and composition for treatment of neoplasms |
| EP3002330A1 (en) | 2005-05-27 | 2016-04-06 | Ospedale San Raffaele S.r.l. | Gene vector |
| PL2325332T3 (en) | 2005-08-26 | 2013-03-29 | Dupont Nutrition Biosci Aps | Use of CRISPR associated genes (CAS) |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| US20080008686A1 (en) | 2006-07-10 | 2008-01-10 | The Brigham And Women's Hospital, Inc. | Tetracycline repressor regulated oncolytic viruses |
| CN105296527B (en) | 2006-08-11 | 2020-11-27 | 陶氏益农公司 | Zinc finger nuclease-mediated homologous recombination |
| WO2008103755A1 (en) | 2007-02-20 | 2008-08-28 | Mayo Foundation For Medical Education And Research | Treating cancer with viral nucleic acid |
| EP2144632B1 (en) | 2007-05-09 | 2016-11-16 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
| US20080289058A1 (en) | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
| WO2009111892A1 (en) | 2008-03-14 | 2009-09-17 | Ottawa Health Research Institute | Microrna mediated oncolytic targeting |
| GB0807424D0 (en) | 2008-04-23 | 2008-05-28 | Isis Innovation | Virus |
| EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | Use of oncolytic herpes viruses for killing cancer stem cells |
| PT2293804E (en) | 2008-05-29 | 2013-08-29 | Univ Bologna Alma Mater | Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof |
| GB0810912D0 (en) | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
| WO2010011961A2 (en) | 2008-07-25 | 2010-01-28 | University Of Georgia Research Foundation, Inc. | Prokaryotic rnai-like system and methods of use |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
| RU2570562C2 (en) | 2008-11-07 | 2015-12-10 | ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС | Bifidobacteria crispr sequences |
| AU2010223888A1 (en) | 2009-03-13 | 2011-10-06 | Egen, Inc. | Compositions and methods for the delivery of biologically active RNAs |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| CA2795695A1 (en) | 2010-04-09 | 2011-10-13 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
| US9593347B2 (en) | 2010-04-16 | 2017-03-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors |
| WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
| EP2630156B1 (en) | 2010-10-20 | 2018-08-22 | DuPont Nutrition Biosciences ApS | Lactococcus crispr-cas sequences |
| SG194089A1 (en) | 2011-04-27 | 2013-11-29 | Amyris Inc | Methods for genomic modification |
| US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
| EP2543734A1 (en) | 2011-07-07 | 2013-01-09 | Deutsches Krebsforschungszentrum | Adeno-parvovirus chimera with enhanced oncolytical potential |
| EP2591796A1 (en) | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| WO2013053775A1 (en) | 2011-10-11 | 2013-04-18 | Universität Zürich Prorektorat Mnw | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013109604A1 (en) | 2012-01-19 | 2013-07-25 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
| DK2836226T3 (en) | 2012-02-24 | 2017-09-18 | Hutchinson Fred Cancer Res | COMPOSITIONS AND PROCEDURES FOR TREATING HEMOGLOBINOPATHY |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| JP6605957B2 (en) * | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス，インコーポレイティド | Compositions and methods for detecting protease activity in biological systems |
| CN105793425B (en) * | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using viral components |
| EP3022307A4 (en) | 2013-07-17 | 2017-04-19 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
| SG11201603119RA (en) | 2013-10-28 | 2016-05-30 | Univ Pittsburgh | Oncolytic hsv vector |
| EP3441084A1 (en) | 2014-02-27 | 2019-02-13 | Viralytics Limited | Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer |
| EP3137105A4 (en) * | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| JP6895374B2 (en) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | Oncolytic virus for expression of immune checkpoint modulator |
| EP4226937A3 (en) | 2015-03-05 | 2023-09-27 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
| US10083137B2 (en) | 2015-04-02 | 2018-09-25 | Atmel Corporation | Peripheral interface circuit for serial memory |
| US9884704B2 (en) | 2015-08-04 | 2018-02-06 | Ernesto A. Aguero-Hernandez | Clip-clamp with top lock device and method |
| US10210575B1 (en) | 2015-08-12 | 2019-02-19 | State Farm Mutual Automobile Insurance Company | System and method of using an image object as a visual data container |
| KR20180051651A (en) * | 2015-10-01 | 2018-05-16 | 히트 바이오로직스, 인코퍼레이티드 | Compositions and methods for adjacent I and II extracellular domains as heterologous chimeric proteins |
| JP6954648B2 (en) | 2015-10-19 | 2021-10-27 | シージー オンコロジー， インコーポレイテッド | Treatment of solid tumors or lymphoid tumors with combination therapy |
| CN108601802A (en) | 2015-12-02 | 2018-09-28 | 纪念斯隆-凯特林癌症中心 | Sai Nika paddy viruses（SVV）The oncotherapy of cell receptor targeting |
| AU2016372576A1 (en) * | 2015-12-17 | 2018-06-21 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
| EP3400292B1 (en) | 2016-01-08 | 2020-08-26 | Replimune Limited | Use of an oncolytic virus for the treatment of cancer |
| AU2017212713B2 (en) | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| WO2017181420A1 (en) | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
| RU2758007C2 (en) * | 2016-06-30 | 2021-10-25 | Онкорус, Инк. | Delivery of therapeutic polypeptides via pseudotyped oncolytic viruses |
| AU2017305335B2 (en) | 2016-08-01 | 2021-11-18 | Virogin Biotech Canada Ltd | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
| CN110050062A (en) | 2016-08-09 | 2019-07-23 | 阿尔莫哈纳德·阿尔卡亚尔 | Express the oncolytic rhabdovirus of IL12 |
| TW201825674A (en) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | Oncolytic virus expressing bispecific engager molecules |
| WO2018085461A1 (en) | 2016-11-01 | 2018-05-11 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| JP2020504767A (en) | 2016-12-21 | 2020-02-13 | メムゲン，エルエルシー | Armed replicable oncolytic adenovirus |
| US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| SG11202000312UA (en) | 2017-07-14 | 2020-02-27 | Oncorus Inc | Encapsulated polynucleotides and methods of use |
| SG11202000691XA (en) | 2017-07-26 | 2020-02-27 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
| EP3941514A4 (en) | 2019-03-20 | 2023-08-30 | Turnstone Biologics Inc. | Sequential heterologous boost oncolytic viral immunotherapy |
| WO2020186356A1 (en) | 2019-03-20 | 2020-09-24 | Turnstone Biologics Inc. | Methods for inducing an immune response against neoantigens |
| WO2021072310A1 (en) | 2019-10-10 | 2021-04-15 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
-
2018
- 2018-07-26 SG SG11202000691XA patent/SG11202000691XA/en unknown
- 2018-07-26 AU AU2018306455A patent/AU2018306455A1/en not_active Abandoned
- 2018-07-26 KR KR1020207005429A patent/KR20200042904A/en not_active Application Discontinuation
- 2018-07-26 MX MX2020000993A patent/MX2020000993A/en unknown
- 2018-07-26 JP JP2020504236A patent/JP7249323B2/en active Active
- 2018-07-26 WO PCT/US2018/043938 patent/WO2019023483A1/en unknown
- 2018-07-26 CA CA3070299A patent/CA3070299A1/en active Pending
- 2018-07-26 CN CN201880057565.XA patent/CN111212656A/en active Pending
- 2018-07-26 EP EP18837388.0A patent/EP3658165A4/en active Pending
- 2018-07-26 RU RU2020108004A patent/RU2771110C2/en active
- 2018-07-26 US US16/633,653 patent/US11612625B2/en active Active
- 2018-07-26 BR BR112020001559-8A patent/BR112020001559A2/en unknown
-
2020
- 2020-01-12 IL IL271993A patent/IL271993A/en unknown
-
2023
- 2023-02-07 US US18/165,770 patent/US20230241140A1/en active Pending
- 2023-03-17 JP JP2023043321A patent/JP2023078309A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3070299A1 (en) | 2019-01-31 |
| US20230241140A1 (en) | 2023-08-03 |
| CN111212656A (en) | 2020-05-29 |
| EP3658165A1 (en) | 2020-06-03 |
| RU2771110C2 (en) | 2022-04-26 |
| US20200206285A1 (en) | 2020-07-02 |
| IL271993A (en) | 2020-02-27 |
| AU2018306455A1 (en) | 2020-02-27 |
| WO2019023483A1 (en) | 2019-01-31 |
| RU2020108004A (en) | 2021-08-26 |
| MX2020000993A (en) | 2020-07-22 |
| JP2020532951A (en) | 2020-11-19 |
| BR112020001559A2 (en) | 2020-08-11 |
| JP7249323B2 (en) | 2023-03-30 |
| RU2020108004A3 (en) | 2021-10-12 |
| EP3658165A4 (en) | 2021-09-01 |
| KR20200042904A (en) | 2020-04-24 |
| JP2023078309A (en) | 2023-06-06 |
| US11612625B2 (en) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290102A (en) | Oncolytic viral vectors and uses thereof | |
| IL271993A (en) | Oncolytic viral vectors and uses thereof | |
| HK1257224A1 (en) | Modified oncolytic virus | |
| IL274218A (en) | Adenovirus vectors and uses thereof | |
| IL282885A (en) | Aav viral vectors and uses thereof | |
| SI3265571T1 (en) | Multiple vector system and uses thereof | |
| EP3518947C0 (en) | Optimized oncolytic viruses and uses thereof | |
| SG11202009009UA (en) | Viral and non-viral nanoplasmid vectors with improved production | |
| GB201706945D0 (en) | Self-inactivating viral vector | |
| IL270989A (en) | Oncolytic virus and method | |
| DK3291841T3 (en) | ONCOLYTIC HSV1 VECTOR AND PROCEDURES | |
| HK1255099A1 (en) | Recombinant oncolytic viruses and uses thereof | |
| IL267450A (en) | Antibodies against lif and uses thereof | |
| EP3624825A4 (en) | Recombinant oncolytic virus | |
| PT3250234T (en) | Recombinant mdv1 and the uses thereof | |
| EP3597759A4 (en) | Borna viral vector and use thereof | |
| EP3371312A4 (en) | Viral vector assay and vector | |
| SG11202101581RA (en) | Oncolytic virus carrying e-cadherin and uses thereof | |
| ZA201906311B (en) | Viral molecular network architecture and design | |
| PT3555132T (en) | Antibodies against lif and uses thereof | |
| GB201621665D0 (en) | Chimeric oncolytic virus | |
| GB201617925D0 (en) | Proteins and uses |